שווי הפעילות העסקית: VYNE Therapeutics (VYNE)

The development of VYNE Therapeutics (VYNE) relies on the test results of BET inhibitors (including VYN201) for skin treatment and partnerships with industry behemoths. Patents for foam formulations and pharmacy distribution protect the business from the mass market. Market price action based on Separate Enterprise Value is recorded at -0.38. Meanwhile, logistics processes and sales have been fully outsourced to external operators, which significantly reduces operating expenses.

The outsourcing model for manufacturing and clinical trials utilized by VYNE Therapeutics allows for the optimization of capital expenditures, which directly impacts the business's cost structure. By analyzing historical EV dynamics, an investor can determine the actual buyout price of the asset through the sum of market capitalization and debt minus liquidity, helping to timely identify overvaluation or the risk of a deep capital drawdown.